HIMS (Hims & Hers Health, Inc.) – Sell Signal Amid Crisis‑Mode Market Regime

Hims & Hers Health, Inc. (NYSE:HIMS) slipped 4.46% to close at $28.07 on 2026‑10‑16 (Friday, US session). The decline comes as LOPJLB’s proprietary model issued a SELL directional signal with a –5 score while the broader market environment is flagged as a CRISIS regime.

News / Catalysts

• Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know – Zacks.com reported that HIMS is once again drawing heightened investor attention, summarizing the company’s recent operational milestones and the lingering volatility in its subscription‑based tele‑health model. The outlet emphasized that the stock’s upside potential is now largely tied to the firm’s ability to sustain its rapid revenue expansion and to convert growing user engagement into profitable earnings.

• Bragar Eagel & Squire, P.C. Reminds Hims & Hers Health, Inc. Investors of the Upcoming Lead Plaintiff Deadline and Urges Investors to Contact the Firm – In a separate filing, the law firm reminded HIMS shareholders of an upcoming lead‑plaintiff deadline in the ongoing consumer‑class‑action litigation. The notice urged investors to contact the firm for guidance, underscoring the legal risk that still hovers over the company’s balance sheet.

Zacks also highlighted that analysts are maintaining a Hold rating on HIMS, with a consensus price target of $32.17. The research note points to the company’s impressive 28% year‑over‑year revenue growth but cautions that the steep negative earnings trajectory and widening operating losses remain material concerns.

The legal reminder from Bragar Eagel & Squire adds another layer of uncertainty, as the deadline could trigger additional disclosures or settlement costs that may affect cash flow and capital allocation in the near term.

Fundamentals and Valuation

HIMS trades at a trailing P/E of –46.02 and a forward P/E of 106.5, reflecting the market’s expectation of a turnaround that has yet to materialize. The company’s price‑to‑book ratio sits at 20.07, while price‑to‑free‑cash‑flow (P/FCF) is 70.24, indicating that investors are paying a premium for each dollar of free cash generated. Enterprise value relative to EBITDA is –94.88, a negative figure driven by persistent EBITDA deficits.

Margins remain thin: gross margin is 64.68%, but operating margin is –3.59% and net margin –5.51%, underscoring the cost pressure of scaling a digital health platform. Return metrics are deeply negative, with ROIC at –18.02%, ROE at –30.03%, and ROA at –3.91%. The PEG ratio of 2.55 suggests that the stock’s growth expectations are not fully justified by its earnings outlook.

Free‑cash‑flow yield stands at 1.42%, and the modest buyback yield of 1.79% offers limited shareholder return in the current environment. The consensus analyst target of $32.17 implies roughly a 14% upside from the last close, yet the Altman Z‑score of 1.63 places the firm in the “grey zone” between healthy and distressed.

Historical Performance

Revenue has accelerated sharply over the past six years, climbing from $148.8 M in 2020 to $2.35 B in 2025 – a compound annual growth rate (CAGR) of roughly 78%. Earnings per share (EPS) moved from a loss of –$0.51 in 2020 to a modest $0.57 in 2025, yet the EPS growth figure of –173.4% in the latest snapshot reflects the volatility of earnings as the firm transitioned from loss‑making to a thinly profitable state in 2024 before slipping again.

Free cash flow (FCF) followed a similar swing: a negative $6.7 M in 2020 turned positive at $73.96 M in 2025, driven largely by the scaling of subscription revenue and improved working‑capital management. However, the FCF yield of 1.42% remains low relative to peers in the broader healthcare sector.

Margin dynamics illustrate the cost of rapid expansion. Gross margins improved from 73.58% (2020) to a peak of 81.99% (2023) before moderating to 79.45% (2024) and 73.84% (2025). Operating margins, once deeply negative (–42.31% in 2021), have narrowed to 4.50% in 2025, indicating better cost control but still insufficient to offset the high customer‑acquisition spend. Net margins have followed a comparable trajectory, moving from –12.18% (2020) to 8.54% (2024) before easing to 5.47% (2025).

Return on equity (ROE) turned positive in 2024 at 26.44%, a notable improvement from double‑digit negatives in prior years, but slipped back to 23.73% in 2025 as earnings pressure resurfaced. Return on assets (ROA) mirrored this pattern, rising to 17.81% in 2024 before falling to 5.96% in 2025.

The balance sheet reflects a debt‑to‑equity ratio of 477.1, indicating a highly leveraged capital structure. While the company’s cash‑generation capacity has improved, the leverage level amplifies financial risk, especially under the current crisis‑mode market regime.

ETF Ownership

HIMS is held by a concentrated set of sector‑focused exchange‑traded funds, with 19 ETFs reporting exposure. The top holders together account for roughly 30% of the float, suggesting that institutional sentiment can move the stock more sharply than a widely dispersed ownership base.

The presence of health‑care‑themed ETFs such as EDOC and HEAL underscores sector‑specific interest in HIMS, yet the relatively modest individual weights mean that any rebalancing by these funds could generate noticeable price pressure, especially in a market environment flagged as a crisis.

LOPJLB Signal Read

LOPJLB’s quantitative engine flags HIMS with a SELL directional signal and a –5 composite score, situating the stock in a CRISIS market regime. The model’s PERF rating of 3.30 and FUND quality score of 6.94 place HIMS in the lower‑mid range of quality metrics, while the Growth score of 30.00 and GARP score of 25.75 highlight that the company is still perceived as a growth‑oriented play despite its deteriorating profitability.

The stock’s Value score is 0.00, confirming that traditional value metrics are not supportive at current levels. The archetype assigned by LOPJLB is Growth Compounder, reflecting the blend of high revenue expansion and still‑emerging earnings stability.

Investors can explore the full overlay of technical and quantitative signals on the interactive chart above this article and review the detailed methodology at the LOPJLB methodology page.

Further research on HIMS is available at the LOPJLB stock hub:

• HIMS Overview & Data
• Screener for Similar Opportunities

The information presented here is for research purposes only and does not constitute investment advice. Readers should conduct their own due diligence and consider their risk tolerance before making any investment decisions.

This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.